European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions.

ABSTRACT: Gastric carcinoma and gastro-oesophageal junction (GC/GEJ) carcinoma remain a significant global problem, with patients presenting with symptoms often found to have advanced or metastatic disease. Treatment options for these patients have broadened in recent years with new chemotherapy agents, agents targeting angiogenic pathways and the development of immune checkpoint inhibitors (ICIs). Most initial advances have occurred in the refractory setting, where it is important to balance treatment benefits versus toxicity and patient quality of life. In the first-line treatment of advanced/metastatic GC/GEJ, platinum- and fluoropyrimidine-based chemotherapy protocols remain the backbone of therapy (with or without HER2-targeted therapy), with the FOLFIRI regimen offering an altern

SUBMITTER: Pavlakis N 

PROVIDER: S-EPMC9425884 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature